UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2026
Commission File Number: 001-38097
ARGENX SE
(Translation of registrant’s name into English)
Laarderhoogtweg 25
1101 EB Amsterdam, the Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
On March 20, 2026, argenx SE (the “Company”)
issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information contained in this Current
Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the Company’s
Registration Statements on Forms S-8 (File Nos. 333-225375, 333-258253, 333-274721,
and 333-292200),
and to be part thereof from the date on which this Current Report on Form 6-K is filed, to the extent not superseded by documents or
reports subsequently filed or furnished.
| Exhibit |
|
Description |
| |
|
|
| 99.1 |
|
Press Release March 20, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
ARGENX SE |
| |
|
|
| Date: March 20, 2026 |
By: |
/s/ Hemamalini
(Malini) Moorthy |
| |
|
Name: Hemamalini (Malini) Moorthy |
| |
|
Title: General Counsel |
Exhibit 99.1
argenx
announces Annual General Meeting of Shareholders on May 6, 2026
March
20, 2026
Amsterdam,
the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives
of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00
CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.
The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The
formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and
registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on
www.abnamro.com/evoting.
Agenda
In addition to recurrent items on
the agenda, such as the discussion and adoption of the 2025 annual accounts, an advisory vote on the company’s 2025 remuneration
report, the discharge of the directors for their duties performed in 2025 and the authorization of the Board of Directors to issue shares
and to limit or exclude pre-emptive rights in relation thereto, the following changes to the Board of Directors are also proposed:
| - | Appointment of Karen Massey as executive director to the Board for a term of 4 years |
| - | Appointment of Tim Van Hauwermeiren as non-executive director to the Board for a term of 4 years |
| - | Re-appointment of Ana Céspedes as non-executive director to the Board of Directors for a term of
4 years |
| - | Re-appointment of Camilla Sylvest as non-executive director to the Board of Directors for a term of 4
years |
| - | Re-appointment of Pamela Klein as a non-executive director to the Board of Directors for a term of 2 years |
Jim Daly to retire as non-executive director
and Chair of the Commercialization Committee, effective May 6, 2026
Mr. Daly has served as a non-executive director
since May 2018. The Board of Directors is currently examining the options for succession of Jim Daly as Chair of the Commercialization
Committee.
“I would like to express my deep gratitude
to Jim for his significant contributions during his tenure with argenx. His contributions as Chair of the Commercialization Committee
have been instrumental in architecting our commercial operations and guiding us through multiple product launches, while supporting our
entrepreneurial spirit and commitment to innovation.” commented Mr. Peter Verhaeghe.
The agenda for the
meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection
at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com.
argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred
to in the convocation.
About argenx
argenx is a global immunology company committed
to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its
Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based
medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad
potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic
franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook,
and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
